"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

The major averages opened the season broadly lower, with the Dow and S&P 500 continuing yesterday’s declines amid ongoing uncertainty around ...

U.S. equities traded higher Wednesday afternoon, near session highs, after Tuesday’s sharp selloff, which erased the S&P 500’s post-election gains. Autos, materials, builders, transports, and pharma ...

Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to ...

The stock makes the NASDAQ top percentage gainers list on acquisition news today, currently trading at $8.44, up 3.48, ...

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

The transaction terms involve Jazz commencing an all-cash tender offer to acquire all outstanding shares of Chimerix’s common ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...